Leerink Partnrs Issues Pessimistic Estimate for TMO Earnings

Key Points

• Leerink Partners revised down their Q1 2026 earnings estimate for Thermo Fisher Scientific to $5.57 from a previous estimate of $5.63, while full-year earnings are expected at $23.28 per share.
• HSBC reaffirmed a "hold" rating with a target price of $510.00, while JPMorgan raised the target price from $600.00 to $650.00 and maintained an "overweight" rating.
• Despite recent earnings beating estimates with $5.79 EPS, the company's growth prospects are being re-evaluated, leading to mixed analyst ratings, with a consensus of "Moderate Buy."

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Equities researchers at Leerink Partnrs dropped their Q1 2026 earnings estimates for Thermo Fisher Scientific in a note issued to investors on Wednesday, October 22nd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $5.57 for the quarter, down from their prior estimate of $5.63. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q3 2026 earnings at $6.11 EPS and FY2026 earnings at $24.53 EPS.

A number of other equities analysts have also recently commented on TMO. HSBC reaffirmed a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Cowen reaffirmed a "buy" rating on shares of Thermo Fisher Scientific in a report on Thursday. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, October 12th. JPMorgan Chase & Co. lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a report on Thursday, October 9th. Finally, TD Cowen boosted their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a "buy" rating in a research note on Thursday. Nineteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $595.75.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $571.94 on Friday. The firm's fifty day simple moving average is $502.38 and its 200-day simple moving average is $452.23. The stock has a market capitalization of $215.97 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 3.25 and a beta of 0.77. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts' consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts' expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company's quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently made changes to their positions in the stock. Mondrian Investment Partners LTD boosted its position in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after purchasing an additional 127,357 shares in the last quarter. Caledonia Investments PLC boosted its position in shares of Thermo Fisher Scientific by 11.5% during the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock worth $45,299,000 after purchasing an additional 11,500 shares in the last quarter. Foresight Group Ltd Liability Partnership boosted its position in shares of Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock worth $29,113,000 after purchasing an additional 56,747 shares in the last quarter. Advisors Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 6.7% in the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after buying an additional 7,967 shares in the last quarter. Finally, New England Research & Management Inc. boosted its position in shares of Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock worth $1,033,000 after buying an additional 567 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock worth $13,990,971 over the last three months. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.